For many women, motherhood is not a barrier but a catalyst. In conjunction with Mothers Day, four mothers share how raising a ...
Morning Overview on MSN
Scientists use sunlight to turn plastic waste into clean hydrogen fuel — solving two problems with one reaction
A drink bottle, a worn-out pair of tights, and a chunk of old mattress foam don’t have much in common, except that all three ...
Forbes contributors publish independent expert analyses and insights. Adia Harvey Wingfield is an author and a professor of sociology. By early 2025, JP Morgan Chase CEO Jamie Dimon had had enough. In ...
Synthetic” and “natural” are largely useless terms. But not “semisynthetic.” It’s a real word that describes a critical ...
Psychedelic-assisted therapy is the subject of renewed focus. It involves using psilocybin—a substance found in psychoactive ...
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition ...
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...
Angelini Pharma said on Thursday that it will acquire Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker's entry into the U.S. pharmaceutical market.
After a crush of promises in 2016 that autonomous cars would soon rule the road, companies whose tech underpinned them have ...
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results